CDMO– tag –
-
Transcenta Therapeutics and WuXi Biologics Forge Strategic Alliance to Expedite Commercialization of HiCB Continuous Bioprocessing Technologies
BioSpace USA Overview Transcenta Therapeutics and WuXi Biologics have entered a strategic collaboration to accelerate the commercialization and deployment of Transcenta's proprietary High-Intensity Continuous Bioprocessing (HiCB) platfor... -
Integrated Advances in CHO Cell Engineering, Media, Perfusion, and PAT Drive Next-Gen Productivity Leap in Mammalian Cell Culture
Pharma's Almanac USA Overview Volumetric productivity in mammalian cell culture, particularly with CHO cells, has dramatically increased due to integrated advancements in cell engineering, media optimization, high-density seeding, fed-ba... -
Samsung Biologics Inks $262M Manufacturing Deal with European Pharma, Propelling Songdo Expansion and Exceeding $21.9 Billion in Cumulative Contracts
BioProcess International USA Overview Samsung Biologics has announced a $262 million manufacturing contract with a European pharmaceutical company, extending through the end of 2033. Production will occur at the company’s manufacturing b... -
Australia’s VVMF Sydney Facility Secures TGA GMP License for Gene and Cell Therapy Manufacturing, Bolstering Domestic CDMO Capacity
Contract Pharma USA Overview Australia's Viral Vector Manufacturing Facility (VVMF) has officially received a Therapeutic Goods Administration (TGA) GMP license for therapeutic product manufacturing at its Sydney site, effective Septembe... -
Northway Biotech Unveils €61M Lithuanian Facility to Industrialize CAR-T, Integrating Vector Supply for Next-Gen Therapies
Invest Lithuania Lithuania Overview Northway Biotech has inaugurated a €61 million, 3,500 sq. meter CDMO facility in Vilnius, Lithuania, designed to industrialize the manufacturing of allogeneic CAR-T and other advanced cell and gene the... -
Cell-Easy Expands Toulouse R&D to Scale Allogeneic NK Cell Therapy (10x Cost Reduction), Optimize G-Rex® CAR-T, and Advance iPSC-Derived Beta Cells
Cell-Easy (press release) France Overview Cell-Easy, a CDMO, announced the expansion of its Toulouse R&D facilities to accelerate three next-generation cell therapy manufacturing programs. The company aims for a ten-fold cost reducti... -
US Trade Policy and BIOSECURE Act Drive Major Reshaping and Investment in Global ADC Manufacturing Landscape
Bioprocess Online USA Overview U.S. trade policy and the BIOSECURE Act are significantly reshaping the Antibody-Drug Conjugate (ADC) manufacturing landscape, spurring substantial investments in capacity across the U.S., Europe, and Asia.... -
Catalent Secures $4.1B Refinancing, Fuels Major Expansion in Biologics and Oral Drug Manufacturing to Meet GLP-1 Demand
Pharmaceutical Technology USA Overview Catalent successfully completed a $4.1 billion debt refinancing, earmarking substantial capital for expanding its biologics and oral drug manufacturing capacity. These strategic investments, includi... -
Merck KGaA to Acquire Bio-Techne for $11.3 Billion, Bolstering Life Science Tools for Cell and Gene Therapy Workflows
BioBucks United States Overview Merck KGaA has agreed to acquire life science tools provider Bio-Techne for $11.3 billion, a strategic move to significantly enhance its life science division. This acquisition deepens Merck KGaA's exposur... -
Global Cell and Gene Therapy Manufacturing Services Market to Surge to $31.3 Billion by 2035, Driven by Regulatory Modernization
openPR.com (DataM Intelligence) Global Overview According to DataM Intelligence, the global cell and gene therapy manufacturing services market is projected to reach $8.77 billion in 2026, growing rapidly to $31.3 billion by 2035 with a ...
